Symbols / HBIO $4.87 -2.79%
HBIO Chart
About
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 215.16M |
| Enterprise Value | 49.60M | Income | -56.70M | Sales | 86.55M |
| Book/sh | 3.08 | Cash/sh | 1.93 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 6.09 | PEG | — |
| P/S | 2.49 | P/B | 1.58 | P/C | — |
| EV/EBITDA | 8.24 | EV/Sales | 0.57 | Quick Ratio | 1.12 |
| Current Ratio | 2.20 | Debt/Eq | 261.18 | LT Debt/Eq | — |
| EPS (ttm) | -1.28 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | -3.30% | Earnings | 2026-05-11 | ROA | 0.04% |
| ROE | -147.13% | ROIC | — | Gross Margin | 57.67% |
| Oper. Margin | 7.21% | Profit Margin | -65.51% | Shs Outstand | 44.18M |
| Shs Float | 3.51M | Short Float | 1.33% | Short Ratio | 0.88 |
| Short Interest | — | 52W High | 9.50 | 52W Low | 2.80 |
| Beta | 1.45 | Avg Volume | 44.93K | Volume | 81.08K |
| Target Price | $6.00 | Recom | Buy | Prev Close | $5.01 |
| Price | $4.87 | Change | -2.79% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$4.87
Latest analyst target
3. DCF / Fair value
$3.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.87
Low
$6.00
High
$6.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | Benchmark | Speculative Buy → Speculative Buy | $1 |
| 2025-09-10 | main | Benchmark | Speculative Buy → Speculative Buy | $2 |
| 2025-05-13 | main | Benchmark | Speculative Buy → Speculative Buy | $3 |
| 2025-04-09 | down | Keybanc | Overweight → Sector Weight | — |
| 2025-04-08 | down | Keybanc | Overweight → Sector Weight | — |
| 2025-03-24 | main | Benchmark | Speculative Buy → Speculative Buy | $5 |
| 2023-06-22 | reit | Benchmark | Speculative Buy → Speculative Buy | $7 |
| 2023-04-26 | main | Benchmark | — → Buy | $7 |
| 2023-04-26 | main | Keybanc | — → Overweight | $7 |
| 2023-03-10 | reit | Benchmark | — → Buy | $4 |
| 2022-11-09 | main | Keybanc | — → Overweight | $5 |
| 2022-08-05 | main | Keybanc | — → Overweight | $7 |
| 2020-11-10 | init | Keybanc | — → Overweight | $6 |
| 2020-02-27 | main | Benchmark | — → Speculative Buy | $4 |
| 2016-11-17 | init | Singular Research | — → Buy | $6 |
| 2015-07-28 | init | Benchmark | — → Buy | $8 |
| 2013-11-26 | up | Sidoti & Co. | Neutral → Buy | — |
- Life science tools firm absorbs $48M hit, eyes 2026 growth - Stock Titan hu, 12 Mar 2026 11
- HBIO: Benchmark Raises Price Target to $6.00, Maintains Speculat - GuruFocus Mon, 16 Mar 2026 14
- Further Upside For Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Introduce Price Risks After 27% Bounce - simplywall.st hu, 04 Dec 2025 08
- Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance hu, 26 Feb 2026 08
- Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena hu, 12 Feb 2026 08
- Gossamer Bio stock tumbles 80% on trial miss - Investing.com Mon, 23 Feb 2026 08
- Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook - Benzinga Fri, 13 Mar 2026 17
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Motley Fool ue, 03 Mar 2026 08
- Harvard Bioscience Stock Jump Looks Great, But How Secure Is That Gain? - Trefis Mon, 22 Dec 2025 08
- Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits Mon, 23 Feb 2026 16
- Harvard Bioscience to turn 10 shares into 1 in March split - Stock Titan Fri, 06 Mar 2026 08
- HBIO: Analyst Bruce D. Jackson Maintains Rating but Lowers Price Target | HBIO Stock News - GuruFocus Fri, 13 Mar 2026 14
- Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com Wed, 11 Mar 2026 11
- Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis Fri, 06 Mar 2026 08
- What's Going On With Harvard Bioscience Stock Friday? - Harvard Bioscience (NASDAQ:HBIO) - Benzinga Fri, 30 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 110000 | — | — | Stock Award(Grant) at price 0.00 per share. | SNIDER WILLIAM | Director | — | 2025-12-17 00:00:00 | D |
| 1 | 110000 | — | — | Stock Award(Grant) at price 0.00 per share. | DENELSKY STEPHEN J | Director | — | 2025-09-05 00:00:00 | D |
| 2 | 1000000 | — | — | Stock Award(Grant) at price 0.00 per share. | DUKE JOHN D. | Chief Executive Officer | — | 2025-08-08 00:00:00 | D |
| 3 | 110000 | — | — | Stock Award(Grant) at price 0.00 per share. | GAGNON ROBERT E | Director | — | 2025-07-16 00:00:00 | D |
| 4 | 110000 | — | — | Stock Award(Grant) at price 0.00 per share. | EADE KATHERINE ANNE | Director | — | 2025-07-16 00:00:00 | D |
| 5 | 110000 | — | — | Stock Award(Grant) at price 0.00 per share. | BENSON SETH BENJAMIN | Director | — | 2025-07-16 00:00:00 | D |
| 6 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | FROST MARK T | Chief Financial Officer | — | 2025-05-12 00:00:00 | D |
| 7 | 10000 | 29100 | — | Purchase at price 2.91 per share. | GREEN JAMES W | Chief Executive Officer | — | 2024-06-13 00:00:00 | D |
| 8 | 20000 | 61400 | — | Purchase at price 3.07 per share. | GREEN JAMES W | Chief Executive Officer | — | 2024-06-06 00:00:00 | D |
| 9 | 45872 | — | — | Stock Award(Grant) at price 0.00 per share. | LOEWALD THOMAS W | Director | — | 2024-05-21 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -334.53K | -132.72K | 48.93K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | 294.00K | 8.66M | 711.00K | 9.02M |
| TotalUnusualItems | -1.59M | -632.00K | 233.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -1.59M | -632.00K | 233.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.40M | -3.42M | -9.52M | -288.00K |
| ReconciledDepreciation | 7.16M | 7.00M | 7.58M | 7.62M |
| ReconciledCostOfRevenue | 37.47M | 44.71M | 51.06M | 49.47M |
| EBITDA | -1.30M | 8.03M | 944.00K | 9.02M |
| EBIT | -8.46M | 1.03M | -6.63M | 1.40M |
| NetInterestIncome | -3.21M | -3.59M | -2.55M | -1.54M |
| InterestExpense | 3.21M | 3.59M | 2.55M | 1.54M |
| NormalizedIncome | -11.15M | -2.92M | -9.70M | -288.00K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.40M | -3.42M | -9.52M | -288.00K |
| TotalExpenses | 100.35M | 110.36M | 120.50M | 116.84M |
| TotalOperatingIncomeAsReported | -6.21M | 1.89M | -6.93M | 2.07M |
| DilutedAverageShares | 43.54M | 42.42M | 41.41M | 40.34M |
| BasicAverageShares | 43.54M | 42.42M | 41.41M | 40.34M |
| DilutedEPS | -0.28 | -0.08 | -0.23 | -0.01 |
| BasicEPS | -0.28 | -0.08 | -0.23 | -0.01 |
| DilutedNIAvailtoComStockholders | -12.40M | -3.42M | -9.52M | -288.00K |
| NetIncomeCommonStockholders | -12.40M | -3.42M | -9.52M | -288.00K |
| NetIncome | -12.40M | -3.42M | -9.52M | -288.00K |
| NetIncomeIncludingNoncontrollingInterests | -12.40M | -3.42M | -9.52M | -288.00K |
| NetIncomeContinuousOperations | -12.40M | -3.42M | -9.52M | -288.00K |
| TaxProvision | 740.00K | 859.00K | 337.00K | 148.00K |
| PretaxIncome | -11.66M | -2.56M | -9.18M | -140.00K |
| OtherIncomeExpense | -2.25M | -859.00K | 535.00K | -666.00K |
| OtherNonOperatingIncomeExpenses | -652.00K | -227.00K | 302.00K | -666.00K |
| SpecialIncomeCharges | 0.00 | 233.00K | 0.00 | |
| OtherSpecialCharges | -233.00K | |||
| GainOnSaleOfSecurity | -1.59M | -632.00K | ||
| NetNonOperatingInterestIncomeExpense | -3.21M | -3.59M | -2.55M | -1.54M |
| InterestExpenseNonOperating | 3.21M | 3.59M | 2.55M | 1.54M |
| OperatingIncome | -6.21M | 1.89M | -7.17M | 2.07M |
| OperatingExpense | 60.98M | 64.18M | 67.98M | 65.59M |
| OtherOperatingExpenses | 1.61M | 71.00K | ||
| DepreciationAmortizationDepletionIncomeStatement | 5.25M | 5.53M | 6.12M | 5.84M |
| DepreciationAndAmortizationInIncomeStatement | 5.25M | 5.53M | 6.12M | 5.84M |
| Amortization | 5.25M | 5.53M | 6.12M | 5.84M |
| AmortizationOfIntangiblesIncomeStatement | 5.25M | 5.53M | 6.12M | 5.84M |
| ResearchAndDevelopment | 10.41M | 11.76M | 12.33M | 10.80M |
| SellingGeneralAndAdministration | 43.70M | 46.82M | 49.53M | 48.95M |
| SellingAndMarketingExpense | 22.21M | 24.06M | 25.04M | 24.64M |
| GeneralAndAdministrativeExpense | 21.49M | 22.76M | 24.49M | 24.30M |
| OtherGandA | 21.49M | 22.76M | 24.49M | 24.30M |
| GrossProfit | 54.77M | 66.07M | 60.82M | 67.65M |
| CostOfRevenue | 39.37M | 46.18M | 52.52M | 51.25M |
| TotalRevenue | 94.14M | 112.25M | 113.33M | 118.90M |
| OperatingRevenue | 94.14M | 112.25M | 113.33M | 118.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 44.07M | 43.39M | 42.08M | 41.14M |
| ShareIssued | 44.07M | 43.39M | 42.08M | 41.14M |
| NetDebt | 32.85M | 32.28M | 42.32M | 40.51M |
| TotalDebt | 44.49M | 42.77M | 54.24M | 56.96M |
| TangibleBookValue | -4.12M | -27.00K | -5.05M | -1.67M |
| InvestedCapital | 100.30M | 109.64M | 119.04M | 131.73M |
| WorkingCapital | -9.84M | 22.50M | 27.88M | 36.27M |
| NetTangibleAssets | -4.12M | -27.00K | -5.05M | -1.67M |
| CapitalLeaseObligations | 7.54M | 6.21M | 7.42M | 8.63M |
| CommonStockEquity | 63.34M | 73.07M | 72.22M | 83.40M |
| TotalCapitalization | 63.34M | 103.78M | 115.23M | 128.50M |
| TotalEquityGrossMinorityInterest | 63.34M | 73.07M | 72.22M | 83.40M |
| StockholdersEquity | 63.34M | 73.07M | 72.22M | 83.40M |
| GainsLossesNotAffectingRetainedEarnings | -15.67M | -14.19M | -15.05M | -10.03M |
| OtherEquityAdjustments | -15.67M | -14.19M | -15.05M | -10.03M |
| TreasuryStock | 0.00 | 0.00 | ||
| RetainedEarnings | -158.01M | -145.60M | -142.19M | -132.67M |
| AdditionalPaidInCapital | 236.58M | 232.44M | 229.01M | 225.65M |
| CapitalStock | 441.00K | 434.00K | 454.00K | 452.00K |
| CommonStock | 441.00K | 434.00K | 454.00K | 452.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 63.30M | 64.29M | 73.14M | 78.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.35M | 37.75M | 49.89M | 53.63M |
| OtherNonCurrentLiabilities | 1.25M | 1.48M | 1.01M | 486.00K |
| NonCurrentDeferredLiabilities | 710.00K | 776.00K | 590.00K | 1.56M |
| NonCurrentDeferredTaxesLiabilities | 710.00K | 776.00K | 590.00K | 1.56M |
| LongTermDebtAndCapitalLeaseObligation | 6.38M | 35.50M | 48.30M | 51.58M |
| LongTermCapitalLeaseObligation | 6.38M | 4.79M | 5.28M | 6.49M |
| LongTermDebt | 30.70M | 43.01M | 45.09M | |
| CurrentLiabilities | 54.96M | 26.54M | 23.25M | 25.32M |
| OtherCurrentLiabilities | 6.54M | 5.28M | 4.01M | 4.25M |
| CurrentDeferredLiabilities | 3.81M | 4.51M | 3.37M | 4.27M |
| CurrentDeferredRevenue | 3.81M | 4.51M | 3.37M | 4.27M |
| CurrentDebtAndCapitalLeaseObligation | 38.11M | 7.28M | 5.95M | 5.38M |
| CurrentCapitalLeaseObligation | 1.16M | 1.42M | 2.13M | 2.14M |
| CurrentDebt | 36.96M | 5.86M | 3.81M | 3.23M |
| OtherCurrentBorrowings | 36.96M | 5.86M | 3.81M | 3.23M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.71M | 3.93M | 3.48M | 6.05M |
| CurrentProvisions | 268.00K | 240.00K | ||
| PayablesAndAccruedExpenses | 4.79M | 5.55M | 6.45M | 5.13M |
| Payables | 4.79M | 5.55M | 6.45M | 5.13M |
| TotalTaxPayable | 0.00 | 224.00K | ||
| IncomeTaxPayable | 0.00 | 224.00K | ||
| AccountsPayable | 4.79M | 5.55M | 6.45M | 4.91M |
| TotalAssets | 126.64M | 137.37M | 145.36M | 162.34M |
| TotalNonCurrentAssets | 81.53M | 88.33M | 94.24M | 100.76M |
| OtherNonCurrentAssets | 2.83M | 6.47M | 7.78M | 5.38M |
| GoodwillAndOtherIntangibleAssets | 67.46M | 73.10M | 77.27M | 85.07M |
| OtherIntangibleAssets | 11.13M | 16.04M | 21.01M | 27.39M |
| Goodwill | 56.32M | 57.06M | 56.26M | 57.69M |
| NetPPE | 11.24M | 8.75M | 9.18M | 10.31M |
| AccumulatedDepreciation | -15.82M | -14.38M | -14.85M | -14.45M |
| GrossPPE | 27.06M | 23.14M | 24.03M | 24.76M |
| Leases | 2.56M | 2.42M | 2.51M | 2.56M |
| OtherProperties | 6.13M | 4.77M | 5.82M | 6.90M |
| MachineryFurnitureEquipment | 18.36M | 15.95M | 15.71M | 15.30M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 45.12M | 49.04M | 51.12M | 61.58M |
| OtherCurrentAssets | 2.90M | 3.94M | 3.47M | 4.34M |
| Inventory | 23.25M | 24.72M | 26.44M | 27.59M |
| FinishedGoods | 5.22M | 5.12M | 5.22M | 5.65M |
| WorkInProcess | 2.75M | 4.19M | 3.78M | 3.41M |
| RawMaterials | 15.27M | 15.41M | 17.44M | 18.53M |
| Receivables | 14.87M | 16.10M | 16.70M | 21.83M |
| AccountsReceivable | 14.87M | 16.10M | 16.70M | 21.83M |
| AllowanceForDoubtfulAccountsReceivable | -215.00K | -160.00K | -191.00K | -136.00K |
| GrossAccountsReceivable | 15.08M | 16.26M | 16.90M | 21.97M |
| CashCashEquivalentsAndShortTermInvestments | 4.11M | 4.28M | 4.51M | 7.82M |
| CashAndCashEquivalents | 4.11M | 4.28M | 4.51M | 7.82M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.82M | 11.72M | -438.00K | -83.00K |
| RepaymentOfDebt | -8.57M | -15.04M | -9.59M | -4.20M |
| IssuanceOfDebt | 8.80M | 4.50M | 7.80M | 4.25M |
| CapitalExpenditure | -3.26M | -2.31M | -1.59M | -1.34M |
| InterestPaidSupplementalData | 3.23M | 3.79M | 2.31M | 1.58M |
| IncomeTaxPaidSupplementalData | 207.00K | 534.00K | 577.00K | |
| EndCashPosition | 4.11M | 4.28M | 4.51M | 7.82M |
| BeginningCashPosition | 4.28M | 4.51M | 7.82M | 8.32M |
| EffectOfExchangeRateChanges | -140.00K | -320.00K | -38.00K | -161.00K |
| ChangesInCash | -35.00K | 95.00K | -3.27M | -335.00K |
| FinancingCashFlow | -131.00K | -12.13M | -2.84M | -252.00K |
| CashFlowFromContinuingFinancingActivities | -131.00K | -12.13M | -2.84M | -252.00K |
| NetOtherFinancingCharges | -738.00K | -2.52M | -1.63M | -3.62M |
| ProceedsFromStockOptionExercised | 380.00K | 930.00K | 577.00K | 3.31M |
| NetIssuancePaymentsOfDebt | 227.00K | -10.54M | -1.79M | 50.00K |
| NetShortTermDebtIssuance | 1.40M | 2.05M | ||
| ShortTermDebtPayments | -6.40M | -2.20M | ||
| ShortTermDebtIssuance | 7.80M | 4.25M | ||
| NetLongTermDebtIssuance | 227.00K | -10.54M | -1.79M | -2.00M |
| LongTermDebtPayments | -8.57M | -15.04M | -9.59M | -2.00M |
| LongTermDebtIssuance | 8.80M | 4.50M | 7.80M | 4.25M |
| InvestingCashFlow | -1.34M | -1.80M | -1.59M | -1.34M |
| CashFlowFromContinuingInvestingActivities | -1.34M | -1.80M | -1.59M | -1.34M |
| NetInvestmentPurchaseAndSale | 1.92M | 0.00 | ||
| SaleOfInvestment | 1.92M | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | 512.00K | 0.00 | |
| SaleOfBusiness | 0.00 | 512.00K | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -150.00K | ||
| PurchaseOfIntangibles | 0.00 | -150.00K | ||
| NetPPEPurchaseAndSale | -2.64M | -1.79M | -1.59M | -1.20M |
| PurchaseOfPPE | -2.64M | -1.79M | -1.59M | -1.20M |
| CapitalExpenditureReported | -619.00K | -523.00K | 0.00 | |
| OperatingCashFlow | 1.44M | 14.03M | 1.15M | 1.26M |
| CashFlowFromContinuingOperatingActivities | 1.44M | 14.03M | 1.15M | 1.26M |
| ChangeInWorkingCapital | 65.00K | 4.60M | 2.72M | -10.19M |
| ChangeInOtherWorkingCapital | -702.00K | 1.14M | -896.00K | 505.00K |
| ChangeInOtherCurrentLiabilities | -1.08M | -495.00K | -2.56M | |
| ChangeInOtherCurrentAssets | 1.64M | 1.65M | 474.00K | -439.00K |
| ChangeInPayablesAndAccruedExpense | -1.78M | -523.00K | -1.40M | 2.45M |
| ChangeInPayable | -1.78M | -523.00K | -1.40M | |
| ChangeInAccountPayable | -1.78M | -523.00K | -1.40M | |
| ChangeInInventory | -64.00K | 1.52M | 252.00K | -5.86M |
| ChangeInReceivables | 974.00K | 810.00K | 4.78M | -4.29M |
| ChangesInAccountReceivables | 974.00K | 810.00K | 4.78M | -4.29M |
| OtherNonCashItems | 327.00K | 280.00K | -3.62M | 280.00K |
| StockBasedCompensation | 4.34M | 5.00M | 4.41M | 4.17M |
| UnrealizedGainLossOnInvestmentSecurities | 632.00K | 0.00 | ||
| DeferredTax | 363.00K | 336.00K | -414.00K | -330.00K |
| DeferredIncomeTax | 363.00K | 336.00K | -414.00K | -330.00K |
| DepreciationAmortizationDepletion | 7.16M | 7.00M | 7.58M | 7.62M |
| DepreciationAndAmortization | 7.16M | 7.00M | 7.58M | 7.62M |
| AmortizationCashFlow | 5.43M | 5.53M | 6.12M | 5.84M |
| AmortizationOfIntangibles | 5.43M | 5.53M | 6.12M | 5.84M |
| Depreciation | 1.73M | 1.47M | 1.45M | 1.78M |
| OperatingGainsLosses | 1.59M | 229.00K | ||
| GainLossOnInvestmentSecurities | 1.59M | 632.00K | ||
| GainLossOnSaleOfBusiness | 0.00 | -403.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -12.40M | -3.42M | -9.52M | -288.00K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HBIO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|